Chahoud J, Msaouel P, Campbell MT, et al. - Researchers assessed the clinical activity of nivolumab in patients with metastatic non-clear cell renal cell carcinoma (nccRCC) with > 20% rhabdoid. They evaluated the objective response rate as the primary endpoint, and progression-free survival (PFS) and overall survival (OS) as secondary endpoints. The study sample included 12 patients (30%) with papillary histology, 11 (27.5%) with unclassified, 8 (20%) with ccRCC with rhabdoid component, 5 (12.5%) having chromophobe, 3 (7.5%) with translocation, and 1 (2.5%) with mucinous tubular and spindle cell carcinoma. An objective response was seen in seven patients, including three who achieved a complete remission. Observations over a median duration of 24.5 months revealed a median PFS and median OS of 4.9 months and 21.7 months, respectively. No treatment-associated deaths were documented. Overall, the activity of nivolumab in unclassified nccRCC and ccRCC with > 20% rhabdoid was evident in this study.